Temporal Trends in Oral Anticoagulant Use and Clinical Outcomes Among Older Adults with Atrial Fibrillation: Insights from a Danish Nationwide Study and Contemporary Evidence

The Danish nationwide study from 1999 to 2022 demonstrated increased uptake of oral anticoagulants (OACs) in older adults with atrial fibrillation (AF), with a significant reduction in stroke incidence across age groups.
Direct oral anticoagulants (DOACs) have improved stroke prevention efficacy and safety profiles compared to vitamin K antagonists (VKAs), especially in elderly and high-risk populations.
In very elderly patients (≥85 years), stroke risk reduction was modest and accompanied by increased intracerebral hemorrhage (ICH) risk, underscoring the need for individualized treatment.
Adherence to anticoagulation and dynamic risk assessment, including bleeding risk monitoring (e.g., HAS-BLED score), are vital to optimize outcomes in elderly AF patients.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

The Danish nationwide study from 1999 to 2022 demonstrated increased uptake of oral anticoagulants (OACs) in older adults with atrial fibrillation (AF), with a significant reduction in stroke incidence across age groups.
Direct oral anticoagulants (DOACs) have improved stroke prevention efficacy and safety profiles compared to vitamin K antagonists (VKAs), especially in elderly and high-risk populations.
In very elderly patients (≥85 years), stroke risk reduction was modest and accompanied by increased intracerebral hemorrhage (ICH) risk, underscoring the need for individualized treatment.
Adherence to anticoagulation and dynamic risk assessment, including bleeding risk monitoring (e.g., HAS-BLED score), are vital to optimize outcomes in elderly AF patients.

Sign in free to continue reading